Lisa R Letourneau1, Siri Atma W Greeley2. 1. Section of Pediatric and Adult Endocrinology, Diabetes, and Metabolism Kovler Diabetes Center, University of Chicago, 5841 S. Maryland Ave., MC1027-N235, Chicago, IL, 60637, USA. 2. Section of Pediatric and Adult Endocrinology, Diabetes, and Metabolism Kovler Diabetes Center, University of Chicago, 5841 S. Maryland Ave., MC1027-N235, Chicago, IL, 60637, USA. sgreeley@peds.bsd.uchicago.edu.
Abstract
PURPOSE OF REVIEW: The goal of this review is to provide updates on the safety and efficacy of long-term sulfonylurea use in patients with KCNJ11-related diabetes. Publications from 2004 to the present were reviewed with an emphasis on literature since 2014. RECENT FINDINGS: Sulfonylureas, often taken at high doses, have now been utilized effectively in KCNJ11 patients for over 10 years. Mild-moderate hypoglycemia can occur, but in two studies with a combined 975 patient-years on sulfonylureas, no severe hypoglycemic events were reported. Improvements in neurodevelopment and motor function after transition to sulfonylureas continue to be described. Sulfonylureas continue to be an effective, sustainable, and safe treatment for KCNJ11-related diabetes. Ongoing follow-up of patients in research registries will allow for deeper understanding of the facilitators and barriers to long-term sustainability. Further understanding of the effect of sulfonylurea on long-term neurodevelopmental outcomes, and the potential for adjunctive therapies, is needed.
PURPOSE OF REVIEW: The goal of this review is to provide updates on the safety and efficacy of long-term sulfonylurea use in patients with KCNJ11-related diabetes. Publications from 2004 to the present were reviewed with an emphasis on literature since 2014. RECENT FINDINGS:Sulfonylureas, often taken at high doses, have now been utilized effectively in KCNJ11patients for over 10 years. Mild-moderate hypoglycemia can occur, but in two studies with a combined 975 patient-years on sulfonylureas, no severe hypoglycemic events were reported. Improvements in neurodevelopment and motor function after transition to sulfonylureas continue to be described. Sulfonylureas continue to be an effective, sustainable, and safe treatment for KCNJ11-related diabetes. Ongoing follow-up of patients in research registries will allow for deeper understanding of the facilitators and barriers to long-term sustainability. Further understanding of the effect of sulfonylurea on long-term neurodevelopmental outcomes, and the potential for adjunctive therapies, is needed.
Authors: Julie Støy; Siri Atma W Greeley; Veronica P Paz; Honggang Ye; Ashley N Pastore; Kinga B Skowron; Rebecca B Lipton; Fran R Cogen; Graeme I Bell; Louis H Philipson Journal: Pediatr Diabetes Date: 2008-07-25 Impact factor: 4.866
Authors: Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Joseph C Koster; Francesco Cadario; Cinzia Peruzzi; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti Journal: J Clin Endocrinol Metab Date: 2007-12-11 Impact factor: 5.958
Authors: Pamela Bowman; Åsta Sulen; Fabrizio Barbetti; Jacques Beltrand; Pernille Svalastoga; Ethel Codner; Ellen H Tessmann; Petur B Juliusson; Torild Skrivarhaug; Ewan R Pearson; Sarah E Flanagan; Tarig Babiker; Nicholas J Thomas; Maggie H Shepherd; Sian Ellard; Iwar Klimes; Magdalena Szopa; Michel Polak; Dario Iafusco; Andrew T Hattersley; Pål R Njølstad Journal: Lancet Diabetes Endocrinol Date: 2018-06-04 Impact factor: 32.069
Authors: Wojciech Fendler; Iwona Pietrzak; Melissa F Brereton; Carolina Lahmann; Mariusz Gadzicki; Malgorzata Bienkiewicz; Izabela Drozdz; Maciej Borowiec; Maciej T Malecki; Frances M Ashcroft; Wojciech M Mlynarski Journal: Diabetes Care Date: 2013-03-05 Impact factor: 19.112
Authors: Tarig Babiker; Natascia Vedovato; Kashyap Patel; Nicholas Thomas; Roisin Finn; Roope Männikkö; Ali J Chakera; Sarah E Flanagan; Maggie H Shepherd; Sian Ellard; Frances M Ashcroft; Andrew T Hattersley Journal: Diabetologia Date: 2016-03-31 Impact factor: 10.122
Authors: Gokhan Dalgin; Andrew K Tryba; Ashley P Cohen; Soo-Young Park; Louis H Philipson; Siri Atma W Greeley; Alfredo J Garcia Journal: Sci Rep Date: 2021-11-03 Impact factor: 4.379